The oral presentation at EHA will include updated safety, complete remission, minimal residual disease (MRD) clinical findings, and longer duration of follow-up. The tuspetinib-based TUS+VEN+AZA ...

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical ... and in an oral presentation and poster at the 18th International ...

“We and our clinical collaborators are particularly ... Copies of the oral and poster presentations will be made available in the ‘Publications & Meetings Presentations’ section of the ...

First Oral Presentation ... a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, ...

May 09, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform ... announced oral and poster presentations highlighting ...

reported data from two clinical presentations at EASL, including rapid and profound anti-HBV responses, and favorable safety and tolerability results, from the first-ever combination therapy with ...

.Over 8,295 and 821 safety days reported in VRON-0200 alone (n=27), and VRON-0200 combination treated patients (n=7), respectively; VRON-0200 was well tolerated, with no serious treatment-related ...